Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy.
Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, SS554-09042 Monserrato (CA), Italy.
J Med Chem. 2021 Jun 24;64(12):8579-8598. doi: 10.1021/acs.jmedchem.1c00535. Epub 2021 Jun 9.
Novel anti-HIV agents are still needed to overcome resistance issues, in particular inhibitors acting against novel viral targets. The ribonuclease H (RNase H) function of the reverse transcriptase (RT) represents a validated and promising target, and no inhibitor has reached the clinical pipeline yet. Here, we present rationally designed non-diketo acid selective RNase H inhibitors (RHIs) based on the quinolinone scaffold starting from former dual integrase (IN)/RNase H quinolinonyl diketo acids. Several derivatives were synthesized and tested against RNase H and viral replication and found active at micromolar concentrations. Docking studies within the RNase H catalytic site, coupled with site-directed mutagenesis, and Mg titration experiments demonstrated that our compounds coordinate the Mg cofactor and interact with amino acids of the RNase H domain that are highly conserved among naïve and treatment-experienced patients. In general, the new inhibitors influenced also the polymerase activity of RT but were selective against RNase H vs the IN enzyme.
仍然需要新型抗 HIV 药物来克服耐药性问题,特别是针对新型病毒靶点的抑制剂。逆转录酶(RT)的核糖核酸酶 H(RNase H)功能是一个已被验证且很有前途的靶点,但目前还没有抑制剂进入临床研发阶段。在这里,我们从以前的双重整合酶(IN)/RNase H 喹啉酮二酮酸出发,基于喹啉酮支架,设计了合理的非二酮酸选择性 RNase H 抑制剂(RHIs)。我们合成了几种衍生物,并对其进行了 RNase H 和病毒复制的测试,发现它们在微摩尔浓度下具有活性。在 RNase H 催化位点内进行的对接研究,结合定点突变和 Mg 滴定实验表明,我们的化合物与 RNase H 结构域中的氨基酸配位,并与 Mg 辅因子相互作用,这些氨基酸在未经治疗和经治疗的患者中高度保守。一般来说,新抑制剂也会影响 RT 的聚合酶活性,但与 IN 酶相比,对 RNase H 具有选择性。